Literature DB >> 30250344

Recombinant Factor VIII Measurement in a Hemophilia A Patient Undergoing Cardiopulmonary Bypass-Supported Cardiac Surgery.

Jennifer Bezaire1, Dorothy Thomson1, Erick McNair1.   

Abstract

Patients with hemophilia A (Hem A) requiring cardiopulmonary bypass-supported cardiac surgery pose unique challenges for perioperative hemostatic management. This report describes a staged perioperative approach to clinical hematologic management as applied to an 80-year-old male of O-positive blood type with mild Hem A, who underwent successful, uncomplicated coronary artery bypass graft surgery. Hematologic management primarily consisted of normalization of plasma factor VIII levels followed by standard care. Conventional laboratory methods and point-of-care-testing methods such as thromboelastography and heparin management assays were combined to guide patient care. Minimal blood loss and minimal hemodilution techniques were also used to achieve favorable outcomes. The thorough preparation and execution of care by our multidisciplinary team from perfusion, pathology and laboratory medicine, cardiovascular surgery, transfusion services, nursing, and anesthesia, facilitated a safe, smooth, clinical course and an optimal outcome.

Entities:  

Keywords:  factor VIII; hemophilia A; point-of-care testing; recombinant factor VIII; thromboelastography

Mesh:

Substances:

Year:  2018        PMID: 30250344      PMCID: PMC6146271     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  26 in total

1.  The "normal" factor VIII concentration in plasma.

Authors:  Saulius Butenas; Behnaz Parhami-Seren; Anetta Undas; David N Fass; Kenneth G Mann
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

2.  Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH.

Authors:  M Chitlur; G E Rivard; D Lillicrap; K Mann; M Shima; G Young
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824

3.  Thromboelastography during coronary artery bypass grafting surgery of severe hemophilia A patient - the effect of heparin and protamine on factor VIII activity.

Authors:  Mudi Misgav; Tal Mandelbaum; Yigal Kassif; Haim Berkenstadt; Ilia Tamarin; Gili Kenet
Journal:  Blood Coagul Fibrinolysis       Date:  2017-06       Impact factor: 1.276

4.  The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study.

Authors:  Keyvan Karkouti; Stuart A McCluskey; Summer Syed; Chris Pazaratz; Humara Poonawala; Mark A Crowther
Journal:  Anesth Analg       Date:  2010-04-30       Impact factor: 5.108

5.  Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.

Authors:  H C A M Hazendonk; J Lock; R A A Mathôt; K Meijer; M Peters; B A P Laros-van Gorkom; F J M van der Meer; M H E Driessens; F W G Leebeek; K Fijnvandraat; M H Cnossen
Journal:  J Thromb Haemost       Date:  2016-02-19       Impact factor: 5.824

6.  Chromogenic factor VIII activity assay.

Authors:  Karen A Moser; Dorothy M Adcock Funk
Journal:  Am J Hematol       Date:  2014-04-15       Impact factor: 10.047

7.  First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study.

Authors:  Klaus Görlinger; Daniel Dirkmann; Alexander A Hanke; Markus Kamler; Eva Kottenberg; Matthias Thielmann; Heinz Jakob; Jürgen Peters
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

8.  Hemophilia A in cardiac operations: a model of reduced thrombin generation.

Authors:  Susanne Lison; Michael Spannagl; Wulf Dietrich
Journal:  Ann Thorac Surg       Date:  2011-05       Impact factor: 4.330

9.  Heparin contamination in coagulation testing and a protocol to avoid it and the risk of inappropriate FFP transfusion.

Authors:  R S Newman; A R Fagin
Journal:  Am J Clin Pathol       Date:  1995-10       Impact factor: 2.493

Review 10.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.